CSIMarket Company Name, Ticker, Industry, else..
 
Quotient Limited  (QTNT)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -139
 Cash Flow (TTM) (Millions $) -116
 Capital Exp. (TTM) (Millions $) 3

Quotient Limited
Quotient Limited is a commercial-stage diagnostics company that develops and commercializes blood grouping and donor disease screening products. Their portfolio includes products for transfusion diagnostics, blood grouping, and immunohematology. Their technologies are designed to provide faster, more accurate, and cost-effective diagnostic solutions for blood transfusion testing. Quotient Limited aims to improve patient outcomes and reduce healthcare costs through their innovative diagnostic products.


   Company Address: Business Park Terre Bonne Eysins 1262
   Company Phone Number: 22-716-9800   Stock Exchange / Ticker: NASDAQ QTNT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Nymox Pharmaceutical Corporation

NYMX, decline in the corporate behavior throughout the October to December 31 2023 span

The investors did not expect any changes at the top-line throughout the the October to December 31 2023 reporting cycle at the Nymox Pharmaceutical Corporation. Yet, shareholders pay very near attention to the In Vitro and In Vivo Diagnostic Substances company's operating shortfall that came in at $-8.35 million, during the same period.

Volitionrx Limited

A bounce in revenue supported to reduce the shortfall, at the company all along the financial period ending June 30 2024

Energetic Revenue rise in its most recent fiscal period, by 82.977 % to $0.40 million supported to cut losses to $-0.08 per share, from $-0.14 in similar financial reporting period a year prior. Volitionrx Limiteds' top-line went up faster in contrast to the the revenue at virtually all of the In Vitro and In Vivo Diagnostic Substances industry contemporaries, in the second quarter of 2024 the majority entities in In Vitro and In Vivo Diagnostic Substances industries experienced an average top-line rise of 6.33% relative to the similar period a year ago.

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc: Revenue Soars, But Profitability Remains Elusive Amid April-June 2024 Surge

company announced very robust Revenue advance year on year to $0.01 million in the second quarter of 2024, but increased a loss per share at $-0.06. Cardio Diagnostics Holdings Inc s' revenue rose at higher rate in contrast to the the top-line at almost all of the In Vitro and In Vivo Diagnostic Substances industry contemporaries, in the second quarter of 2024 the majority entities in In Vitro and In Vivo Diagnostic Substances industries reported the revenue advance of 6.22% relative to the corresponding period a year ago.

Celldex Therapeutics Inc

An extraordinary conduct by Celldex Therapeutics Inc over the second quarter of 2024 earnings season

For the second quarter of 2024 earnings season Celldex Therapeutics Inc decreased a loss per share of $-0.54 per share compare to $-0.65 a year prior and EPS improved from $-0.56 per share from the previous quarter. The revenue advanced sharply by 832.09 % to $2.50 million from $0.27 million in the similar quarter a year prior and sequentially Revenue doubled by 1501.282 % from $0.16 million. In Vitro and In Vivo Diagnostic Substances company's revenue, surge in the second quarter of 2024 correlates favorably to its In Vitro and In Vivo Diagnostic Substances industry peers, which experienced all in all 6.22 % top-line advance in the same period thus far.

Idexx Laboratories Inc

IDEXX Laboratories: Revenue Rises, But Earnings Take a Dive in Q2 2024

IDXX reported contradictory results in the April to June 30 2024 time-frame, where Revenue grew by 6.309 % to $1.00 billion compared to $943.63 million on a year-over-year basis, while earnings decreased by -8.61 % to $2.44 per share, as a comparison to $2.67 in the prior year reporting period. Idexx Laboratories Incs' top-line, growth in the second quarter of 2024 compares favorably to its In Vitro and In Vivo Diagnostic Substances sector contemporaries, which had all in all 4.46 % revenue elevation during the matching time so far.







Quotient Limited's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com